Clinical Trial Results:
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine using Olanzapine as an Active Control in Subjects Diagnosed with Schizophrenia who Completed Protocol P05688 (formerly 041038) (Phase 3B, Protocol P05689 [formerly 041039])
Summary
|
|
EudraCT number |
2010-018408-96 |
Trial protocol |
BG |
Global end of trial date |
06 Mar 2015
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
31 Jan 2019
|
First version publication date |
31 Jan 2019
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
P05689
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01617200 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Forest Research Institute, Inc., an affiliate of Allergan, plc
|
||
Sponsor organisation address |
185 Hudson Street, Jersey City, United States, NJ 07302
|
||
Public contact |
Willie Earley, Forest Research Institute, Inc., an affiliate of Allergan, plc, Willie.Earley@Allergan.com
|
||
Scientific contact |
Willie Earley, Forest Research Institute, Inc., an affiliate of Allergan, plc, Willie.Earley@Allergan.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
06 Mar 2015
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
06 Mar 2015
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
06 Mar 2015
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary objective of this trial was to evaluate the long-term safety of 2.5 and 5 milligram (mg) twice daily (BID) asenapine in schizophrenia subjects.
|
||
Protection of trial subjects |
This trial was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.
|
||
Background therapy |
This was a long-term extension trial for subjects who had completed the 6-week short-term trial P05688. In the previous short-term trial, subjects had been randomly assigned to receive a fixed dose of asenapine (either 2.5 mg or 5 mg BID) or olanzapine 15 mg once daily (QD) or placebo (BID) for 6 weeks. | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
12 Mar 2013
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Russian Federation: 33
|
||
Country: Number of subjects enrolled |
Ukraine: 26
|
||
Country: Number of subjects enrolled |
Bulgaria: 23
|
||
Country: Number of subjects enrolled |
United States: 18
|
||
Country: Number of subjects enrolled |
Romania: 13
|
||
Country: Number of subjects enrolled |
Croatia: 7
|
||
Worldwide total number of subjects |
120
|
||
EEA total number of subjects |
43
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
120
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Recruitment details |
First participant enrolled: 12 March 2013; last participant completed: 6 Mar 2015. This study was performed at 39 sites across the United States, Bulgaria, Romania, Russian Federation, Croatia, and the Ukraine. | ||||||||||||||||||||||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Screening details |
A total of 120 participants who had previously completed the short-term randomized trial P05688 continued in the current extension trial (P05689). Participants randomly assigned to asenapine or olanzapine in P05688 were assigned the same treatment regimen in P05689; participants randomly assigned to placebo were assigned to asenapine 2.5 mg BID. | ||||||||||||||||||||||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Period 1 title |
Overall Study (overall period)
|
||||||||||||||||||||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||||||||||||||||||||||
Allocation method |
Non-randomised - controlled
|
||||||||||||||||||||||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator | ||||||||||||||||||||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Are arms mutually exclusive |
No
|
||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Placebo / Asenapine 2.5 mg | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
In the previous short-term trial PO5688, participants were administered placebo for 42 days; in the current extension trial (PO5689), participants were administered one 2.5 mg asenapine tablet BID for 26 weeks. | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Asenapine
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
Asenapine
|
||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Sublingual tablet
|
||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Sublingual use
|
||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
2.5 mg fast-dissolving active asenapine tablets administered sublingually
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo Olanzapine
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
Placebo Olanzapine
|
||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Film-coated placebo olanzapine tablets (to match 5 and 10 mg active olanzapine tablets) administered orally
|
||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Asenapine 2.5 mg / Asenapine 2.5 mg | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
In the previous short-term trial PO5688, participants were administered one 2.5 mg asenapine tablet BID for 42 days; in the current extension trial (PO5689), participants were assigned to the same treatment regimen (ie, one 2.5 mg asenapine tablet BID) for 26 weeks. | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Asenapine
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
Asenapine
|
||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Sublingual tablet
|
||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Sublingual use
|
||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
2.5 mg fast-dissolving active asenapine tablets administered sublingually
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo Olanzapine
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
Placebo Olanzapine
|
||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Film-coated placebo olanzapine tablets (to match 5 and 10 mg active olanzapine tablets) administered orally
|
||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Asenapine 2.5 mg Overall | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
In the previous short-term trial PO5688, participants were administered either placebo or one 2.5 mg asenapine tablet BID for 42 days; in the current extension trial (PO5689), participants were administered one 2.5 mg asenapine tablet BID for 26 weeks. The 'asenapine 2.5 mg overall' arm represents the 'placebo / asenapine 2.5 mg' and 'asenapine 2.5 mg / asenapine 2.5 mg' arms combined. | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Asenapine
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
Asenapine
|
||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Sublingual tablet
|
||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Sublingual use
|
||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
2.5 mg fast-dissolving active asenapine tablets administered sublingually
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo Olanzapine
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
Placebo Olanzapine
|
||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Film-coated placebo olanzapine tablets (to match 5 and 10 mg active olanzapine tablets) administered orally
|
||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Asenapine 5 mg / Asenapine 5 mg | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
In the previous short-term trial PO5688, participants were administered one 5 mg asenapine tablet BID for 42 days; in the current extension trial (PO5689), participants were assigned to the same treatment regimen (ie, one 5 mg asenapine tablet BID) for 26 weeks. | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Asenapine
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
Asenapine
|
||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Sublingual tablet
|
||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Sublingual use
|
||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
5 mg fast-dissolving active asenapine tablets administered sublingually
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo Olanzapine
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
Placebo Olanzapine
|
||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Film-coated placebo olanzapine tablets (to match 5 and 10 mg active olanzapine tablets) administered orally
|
||||||||||||||||||||||||||||||||||||||||||||||||
Arm title
|
Olanzapine 15 mg / Olanzapine 15 mg | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm description |
In the previous short-term trial PO5688, participants were administered 15 mg olanzapine (as one 10 mg and one 5 mg tablet) QD for 42 days (except during Week 1 when olanzapine 10 mg QD was administered); in the current extension trial (PO5689), participants were assigned to the same treatment regimen (ie, 15 mg olanzapine) for 26 weeks. | ||||||||||||||||||||||||||||||||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Olanzapine
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
Olanzapine
|
||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
5 and 10 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) was not disclosed in order to preserve blinding
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo Olanzapine
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
Placebo Olanzapine
|
||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Film-coated placebo olanzapine tablets (to match 5 and 10 mg active olanzapine tablets) administered orally
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo Asenapine
|
||||||||||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
Placebo Asenapine
|
||||||||||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Sublingual tablet
|
||||||||||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Sublingual use
|
||||||||||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
Fast dissolving placebo asenapine tablets (to match 2.5 mg and 5 mg active asenapine tablets) administered sublingually
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo / Asenapine 2.5 mg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
In the previous short-term trial PO5688, participants were administered placebo for 42 days; in the current extension trial (PO5689), participants were administered one 2.5 mg asenapine tablet BID for 26 weeks. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Asenapine 2.5 mg / Asenapine 2.5 mg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
In the previous short-term trial PO5688, participants were administered one 2.5 mg asenapine tablet BID for 42 days; in the current extension trial (PO5689), participants were assigned to the same treatment regimen (ie, one 2.5 mg asenapine tablet BID) for 26 weeks. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Asenapine 2.5 mg Overall
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
In the previous short-term trial PO5688, participants were administered either placebo or one 2.5 mg asenapine tablet BID for 42 days; in the current extension trial (PO5689), participants were administered one 2.5 mg asenapine tablet BID for 26 weeks. The 'asenapine 2.5 mg overall' arm represents the 'placebo / asenapine 2.5 mg' and 'asenapine 2.5 mg / asenapine 2.5 mg' arms combined. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Asenapine 5 mg / Asenapine 5 mg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
In the previous short-term trial PO5688, participants were administered one 5 mg asenapine tablet BID for 42 days; in the current extension trial (PO5689), participants were assigned to the same treatment regimen (ie, one 5 mg asenapine tablet BID) for 26 weeks. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Olanzapine 15 mg / Olanzapine 15 mg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
In the previous short-term trial PO5688, participants were administered 15 mg olanzapine (as one 10 mg and one 5 mg tablet) QD for 42 days (except during Week 1 when olanzapine 10 mg QD was administered); in the current extension trial (PO5689), participants were assigned to the same treatment regimen (ie, 15 mg olanzapine) for 26 weeks. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Placebo / Asenapine 2.5 mg
|
||
Reporting group description |
In the previous short-term trial PO5688, participants were administered placebo for 42 days; in the current extension trial (PO5689), participants were administered one 2.5 mg asenapine tablet BID for 26 weeks. | ||
Reporting group title |
Asenapine 2.5 mg / Asenapine 2.5 mg
|
||
Reporting group description |
In the previous short-term trial PO5688, participants were administered one 2.5 mg asenapine tablet BID for 42 days; in the current extension trial (PO5689), participants were assigned to the same treatment regimen (ie, one 2.5 mg asenapine tablet BID) for 26 weeks. | ||
Reporting group title |
Asenapine 2.5 mg Overall
|
||
Reporting group description |
In the previous short-term trial PO5688, participants were administered either placebo or one 2.5 mg asenapine tablet BID for 42 days; in the current extension trial (PO5689), participants were administered one 2.5 mg asenapine tablet BID for 26 weeks. The 'asenapine 2.5 mg overall' arm represents the 'placebo / asenapine 2.5 mg' and 'asenapine 2.5 mg / asenapine 2.5 mg' arms combined. | ||
Reporting group title |
Asenapine 5 mg / Asenapine 5 mg
|
||
Reporting group description |
In the previous short-term trial PO5688, participants were administered one 5 mg asenapine tablet BID for 42 days; in the current extension trial (PO5689), participants were assigned to the same treatment regimen (ie, one 5 mg asenapine tablet BID) for 26 weeks. | ||
Reporting group title |
Olanzapine 15 mg / Olanzapine 15 mg
|
||
Reporting group description |
In the previous short-term trial PO5688, participants were administered 15 mg olanzapine (as one 10 mg and one 5 mg tablet) QD for 42 days (except during Week 1 when olanzapine 10 mg QD was administered); in the current extension trial (PO5689), participants were assigned to the same treatment regimen (ie, 15 mg olanzapine) for 26 weeks. |
|
|||||||||||||||||||||||||
End point title |
Change From Trial P05688 Baseline in Body Weight at Day 182 | ||||||||||||||||||||||||
End point description |
Change from short-term trial (P05688) baseline in body weight at Day 182. Population for this analysis was the All Treated Set (ATS), defined as all randomized participants from the short-term trial who received ≥1 dose study drug in the current extension trial (P05689).
|
||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||
End point timeframe |
Baseline (P05688) to Day 182
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||||||||||
Statistical analysis description |
Analysis was performed using a Mixed Model Repeated Measures (MMRM) for the ATS population. The model included change from short-term baseline (Trial P05688) score at each visit as the dependent variable, and terms for treatment, center, visit, treatment by visit interaction, and baseline weight as covariates. There was no multiple hypotheses testing for multiple comparisons.
|
||||||||||||||||||||||||
Comparison groups |
Asenapine 2.5 mg Overall v Olanzapine 15 mg / Olanzapine 15 mg
|
||||||||||||||||||||||||
Number of subjects included in analysis |
78
|
||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||
Parameter type |
LS means difference | ||||||||||||||||||||||||
Point estimate |
-0.6
|
||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||
lower limit |
-3.6 | ||||||||||||||||||||||||
upper limit |
2.4 | ||||||||||||||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||||||||||||||
Dispersion value |
1.49
|
||||||||||||||||||||||||
Statistical analysis title |
Comparison by Treatment Group | ||||||||||||||||||||||||
Statistical analysis description |
Analysis was performed using MMRM for the ATS population. The model included change from short-term baseline (Trial P05688) score at each visit as the dependent variable, and terms for treatment, center, visit, treatment by visit interaction, and baseline weight as covariates. There was no multiple hypotheses testing for multiple comparisons.
|
||||||||||||||||||||||||
Comparison groups |
Asenapine 5 mg / Asenapine 5 mg v Olanzapine 15 mg / Olanzapine 15 mg
|
||||||||||||||||||||||||
Number of subjects included in analysis |
58
|
||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||
Parameter type |
LS means difference | ||||||||||||||||||||||||
Point estimate |
-0.4
|
||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||
lower limit |
-3.6 | ||||||||||||||||||||||||
upper limit |
2.7 | ||||||||||||||||||||||||
Variability estimate |
Standard error of the mean
|
||||||||||||||||||||||||
Dispersion value |
1.59
|
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Change From Trial P05688 Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Days 7, 28, 84, 182, and Study Endpoint [1] | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
The PANSS is a 30-item clinician-rated instrument for assessing schizophrenia symptoms. It consists of 3 subscales: positive subscale (7 items), negative subscale (7 items), and general psychopathology subscale (16 items). For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. The PANSS Total Score for each participant was sum of the rating assigned to each of the 30 PANSS items, and ranged from 30 to 210 with a higher score indicating greater severity of symptoms. The measure reports change from short-term trial baseline (P05688) at each specified visit, analysed using an analysis of covariance (ANCOVA) model adjusted for pooled investigative site and baseline values; improvement in symptoms is represented by negative values. Population for analysis was the Full Analysis Set (FAS), defined as all randomized participants from PO5688 who received ≥1 dose of study drug in PO5689 and had ≥1 post- PANSS Total Score measurement.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Baseline (P05688) and Days 7, 28, 84, 182, and Study Endpoint
|
|||||||||||||||||||||||||||||||||||||||||||||
Notes [1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The end point "Change From Trial P05688 Baseline in PANSS Total Score" was assessed in each of the individual treatment arms: "Placebo / Asenapine 2.5 mg"; "Asenapine 2.5 mg / Asenapine 2.5 mg"; "Asenapine 5 mg / Asenapine 5 mg" and "Olanzapine 15 mg / Olanzapine 15 mg". The 'Asenapine 2.5 mg Overall' arm represents the 'Placebo / Asenapine 2.5 mg' and 'Asenapine 2.5 mg / Asenapine 2.5 mg' arms combined and this combined arm was not included for analysis of this secondary end point. |
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Percentage of Participants Who Are PANSS Responders (≥30% Reduction From Trial P05688 Baseline in PANSS Total Score) at Days 7, 28, 84, 182, and Study Endpoint [2] | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
A PANSS responder was defined as a participant who had a reduction from baseline of at least 30% in the PANSS Total Score at a post-baseline assessment. Responder status was assessed relative to the short-term trial baseline (P05688). The PANSS is a 30-item clinician-rated instrument for assessing schizophrenia symptoms. For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. The Total Score is the sum of the ratings for the individual items, and ranged from 30 to 210 with a higher score indicating greater severity of symptoms. Population for analysis was the FAS, defined as all randomized participants from PO5688 who received ≥1 dose of study drug in PO5689 and had ≥1 post- PANSS Total Score measurement.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Days 7, 28, 84, 182, and Study Endpoint
|
|||||||||||||||||||||||||||||||||||||||||||||
Notes [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The end point "Percentage of Participants Who Are PANSS Responders" was assessed in each of the individual treatment arms: "Placebo / Asenapine 2.5 mg"; "Asenapine 2.5 mg / Asenapine 2.5 mg"; "Asenapine 5 mg / Asenapine 5 mg" and "Olanzapine 15 mg / Olanzapine 15 mg". The 'Asenapine 2.5 mg Overall' arm represents the 'Placebo / Asenapine 2.5 mg' and 'Asenapine 2.5 mg / Asenapine 2.5 mg' arms combined and this combined arm was not included for analysis of this secondary end point. |
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Change From Trial P05688 Baseline in Clinical Global Impression Scale-Severity (CGI-S) Score at Days 7, 14, 28, 56, 84, 112, 182, and Study Endpoint [3] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
The CGI-S is a 7-point scale for assessing the global severity of the participant’s illness, with ratings from 1=normal, not ill to 7=very severely ill. The reported measure is the change from short-term trial baseline (P05688) at each specified visit, analysed using an ANCOVA model adjusted for pooled investigative site and baseline values; improvement in symptoms is represented by negative values. Population for analysis was the FAS, defined as all randomized participants from PO5688 who received ≥1 dose of study drug in PO5689 and had ≥1 post- PANSS Total Score measurement.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Baseline (P05688 ) and Days 7, 14, 28, 56, 84, 112, 182, and Study Endpoint
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The end point "Change From Trial P05688 Baseline in CGI-S Score" was assessed in each of the individual treatment arms: "Placebo / Asenapine 2.5 mg"; "Asenapine 2.5 mg / Asenapine 2.5 mg"; "Asenapine 5 mg / Asenapine 5 mg" and "Olanzapine 15 mg / Olanzapine 15 mg". The 'Asenapine 2.5 mg Overall' arm represents the 'Placebo / Asenapine 2.5 mg' and 'Asenapine 2.5 mg / Asenapine 2.5 mg' arms combined and this combined arm was not included for analysis of this secondary end point. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Percentage of Participants Who Are Clinical Global Impression Scale-Improvement (CGI-I) Responders at Days 7, 14, 28, 56, 84, 112, 182, and Study Endpoint [4] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
A CGI-I responder was defined as a participant who had a CGI-I score of 1 (very much improved) or 2 (much improved) at a post-baseline assessment. Responder status was assessed relative to the short-term trial baseline (P05688). CGI-I is a 7-point scale for assessing the global improvement of the participant’s illness relative to baseline, with ratings from 1=very much improved to 7=very much worse. Population for analysis was the FAS, defined as all randomized participants from PO5688 who received ≥1 dose of study drug in PO5689 and had ≥1 post- PANSS Total Score measurement.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Days 7, 14, 28, 56, 84, 112, 182, and Study Endpoint
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The end point "Percentage of Participants Who Are CGI-I Responders" was assessed in each of the individual treatment arms: "Placebo / Asenapine 2.5 mg"; "Asenapine 2.5 mg / Asenapine 2.5 mg"; "Asenapine 5 mg / Asenapine 5 mg" and "Olanzapine 15 mg / Olanzapine 15 mg". The 'Asenapine 2.5 mg Overall' arm represents the 'Placebo / Asenapine 2.5 mg' and 'Asenapine 2.5 mg / Asenapine 2.5 mg' arms combined and this combined arm was not included for analysis of this secondary end point. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
PANSS Negative Subscale Score at Days 7, 28, 84, 182, and Study Endpoint [5] | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
This measure reports results for the 7 items of the negative subscale of the PANSS, which is a 30-item clinician-rated instrument used to assess schizophrenia symptoms. Negative symptoms represent a diminution or loss of normal functions (e.g., emotional withdrawal). For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. PANSS negative subscale score for each participant was sum of the rating assigned to each of the 7 subscale items, and ranged from 7 to 49 with a higher score indicating greater severity of symptoms. Population for analysis was the FAS, defined as all randomized participants from PO5688 who received ≥1 dose of study drug in PO5689 and had ≥1 post- PANSS Total Score measurement.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Days 7, 28, 84, 182, and Study Endpoint
|
|||||||||||||||||||||||||||||||||||||||||||||
Notes [5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The end point "PANSS Negative Subscale Score" was assessed in each of the individual treatment arms: "Placebo / Asenapine 2.5 mg"; "Asenapine 2.5 mg / Asenapine 2.5 mg"; "Asenapine 5 mg / Asenapine 5 mg" and "Olanzapine 15 mg / Olanzapine 15 mg". The 'Asenapine 2.5 mg Overall' arm represents the 'Placebo / Asenapine 2.5 mg' and 'Asenapine 2.5 mg / Asenapine 2.5 mg' arms combined and this combined arm was not included for analysis of this secondary end point. |
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
PANSS Positive Subscale Score at Days 7, 28, 84, 182, and Study Endpoint [6] | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
This measure reports results for the 7 items of the positive subscale of the PANSS, which is a 30-item clinician-rated instrument used to assess schizophrenia symptoms. Positive symptoms refer to an excess or distortion of normal mental status (e.g., delusions). For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. PANSS positive subscale score for each participant was sum of the rating assigned to each of the 7 subscale items, and ranged from 7 to 49 with a higher score indicating greater severity of symptoms. Population for analysis was the FAS, defined as all randomized participants from PO5688 who received ≥1 dose of study drug in PO5689 and had ≥1 post- PANSS Total Score measurement.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Days 7, 28, 84, 182, and Study Endpoint
|
|||||||||||||||||||||||||||||||||||||||||||||
Notes [6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The end point "PANSS Positive Subscale Score" was assessed in each of the individual treatment arms: "Placebo / Asenapine 2.5 mg"; "Asenapine 2.5 mg / Asenapine 2.5 mg"; "Asenapine 5 mg / Asenapine 5 mg" and "Olanzapine 15 mg / Olanzapine 15 mg". The 'Asenapine 2.5 mg Overall' arm represents the 'Placebo / Asenapine 2.5 mg' and 'Asenapine 2.5 mg / Asenapine 2.5 mg' arms combined and this combined arm was not included for analysis of this secondary end point. |
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
PANSS General Psychopathology Subscale Score at Days 7, 28, 84, 182, and Study Endpoint [7] | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
This measure reports results for the 16 items of the general psychopathology subscale of the PANSS, which is a 30-item clinician-rated instrument used to assess the symptoms of schizophrenia. For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. The PANSS general psychopathology subscale score for each participant was calculated as the sum of the rating assigned to each of the 16 subscale items, and ranged from 16 to 112 with a higher score indicating greater severity of symptoms. Population for analysis was the FAS, defined as all randomized participants from PO5688 who received ≥1 dose of study drug in PO5689 and had ≥1 post- PANSS Total Score measurement.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Days 7, 28, 84, 182, and Study Endpoint
|
|||||||||||||||||||||||||||||||||||||||||||||
Notes [7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The end point "PANSS General Psychopathology Subscale Score" was assessed in each of the individual treatment arms: "Placebo / Asenapine 2.5 mg"; "Asenapine 2.5 mg / Asenapine 2.5 mg"; "Asenapine 5 mg / Asenapine 5 mg" and "Olanzapine 15 mg / Olanzapine 15 mg". The 'Asenapine 2.5 mg Overall' arm represents the 'Placebo / Asenapine 2.5 mg' and 'Asenapine 2.5 mg / Asenapine 2.5 mg' arms combined and this combined arm was not included for analysis of this secondary end point. |
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
PANSS Marder Factor Positive Symptom Score at Days 7, 28, 84, 182, and Study Endpoint [8] | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
This measure reports results for the 8 items of the Marder positive symptom factor of the PANSS, which is a 30-item clinician-rated instrument used to assess schizophrenia symptoms. Marder factors are a modified grouping of the 30 PANSS items. For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. PANSS Marder factor positive symptom score for each participant was sum of rating assigned to each of the 8 applicable Marder factor items, and ranged from 8 to 56 with a higher score indicating greater severity of symptoms. Population for analysis was the FAS, defined as all randomized participants from PO5688 who received ≥1 dose of study drug in PO5689 and had ≥1 post- PANSS Total Score measurement.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Days 7, 28, 84, 182, and Study Endpoint
|
|||||||||||||||||||||||||||||||||||||||||||||
Notes [8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The end point "PANSS Marder Factor Positive Symptom Score" was assessed in each of the individual treatment arms: "Placebo / Asenapine 2.5 mg"; "Asenapine 2.5 mg / Asenapine 2.5 mg"; "Asenapine 5 mg / Asenapine 5 mg" and "Olanzapine 15 mg / Olanzapine 15 mg". The 'Asenapine 2.5 mg Overall' arm represents the 'Placebo / Asenapine 2.5 mg' and 'Asenapine 2.5 mg / Asenapine 2.5 mg' arms combined and this combined arm was not included for analysis of this secondary end point. |
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
PANSS Marder Factor Negative Symptom Score at Days 7, 28, 84, 182, and Study Endpoint [9] | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
This measure reports results for the 7 items of the Marder negative symptoms factor of the PANSS, which is a 30-item clinician-rated instrument used to assess schizophrenia symptoms. Marder factors are a modified grouping of the 30 PANSS items. For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. PANSS Marder factor negative symptom score for each participant was sum of the rating assigned to each of the 7 applicable Marder factor items, and ranged from 7 to 49 with a higher score indicating greater severity of symptoms. Population for analysis was the FAS, defined as all randomized participants from PO5688 who received ≥1 dose of study drug in PO5689 and had ≥1 post- PANSS Total Score measurement.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Days 7, 28, 84, 182, and Study Endpoint
|
|||||||||||||||||||||||||||||||||||||||||||||
Notes [9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The end point "PANSS Marder Factor Negative Symptom Score" was assessed in each of the individual treatment arms: "Placebo / Asenapine 2.5 mg"; "Asenapine 2.5 mg / Asenapine 2.5 mg"; "Asenapine 5 mg / Asenapine 5 mg" and "Olanzapine 15 mg / Olanzapine 15 mg". The 'Asenapine 2.5 mg Overall' arm represents the 'Placebo / Asenapine 2.5 mg' and 'Asenapine 2.5 mg / Asenapine 2.5 mg' arms combined and this combined arm was not included for analysis of this secondary end point. |
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
PANSS Marder Factor Disorganized Thought Symptom Score at Days 7, 28, 84, 182, and Study Endpoint [10] | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
This measure reports results for the 7 items of the Marder disorganized thoughts factor of the PANSS, which is a 30-item clinician-rated instrument used to assess schizophrenia symptoms. Marder factors are a modified grouping of the 30 PANSS items. For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. PANSS Marder factor disorganized thought symptom score for each participant was sum of rating assigned to each of the 7 applicable Marder factor items, and ranged from 7 to 49 with a higher score indicating greater severity of symptoms. Population for analysis was the FAS, defined as all randomized participants from PO5688 who received ≥1 dose of study drug in PO5689 and had ≥1 post- PANSS Total Score measurement.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Days 7, 28, 84, 182, and Study Endpoint
|
|||||||||||||||||||||||||||||||||||||||||||||
Notes [10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The end point "PANSS Marder Factor Disorganized Thought Symptom Score" was assessed in each of the individual treatment arms: "Placebo / Asenapine 2.5 mg"; "Asenapine 2.5 mg / Asenapine 2.5 mg"; "Asenapine 5 mg / Asenapine 5 mg" and "Olanzapine 15 mg / Olanzapine 15 mg". The 'Asenapine 2.5 mg Overall' arm represents the 'Placebo / Asenapine 2.5 mg' and 'Asenapine 2.5 mg / Asenapine 2.5 mg' arms combined and this combined arm was not included for analysis of this secondary end point. |
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
PANSS Marder Factor Hostility/Excitement Symptom Score at Days 7, 28, 84, 182, and Study Endpoint [11] | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
This measure reports results for the 4 items of the Marder hostility/excitement factor of the PANSS, which is a 30-item clinician-rated instrument used to assess schizophrenia symptoms. Marder factors are a modified grouping of the 30 PANSS items. For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. PANSS Marder factor hostility/excitement symptom score for each participant was sum of rating assigned to each of the 4 applicable Marder factor items, and ranged from 4 to 28 with a higher score indicating greater severity of symptoms. Population for analysis was the FAS, defined as all randomized participants from PO5688 who received ≥1 dose of study drug in PO5689 and had ≥1 post- PANSS Total Score measurement.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Days 7, 28, 84, 182, and Study Endpoint
|
|||||||||||||||||||||||||||||||||||||||||||||
Notes [11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The end point "PANSS Marder Factor Hostility/Excitement Symptom Score" was assessed in each of the individual treatment arms: "Placebo / Asenapine 2.5 mg"; "Asenapine 2.5 mg / Asenapine 2.5 mg"; "Asenapine 5 mg / Asenapine 5 mg" and "Olanzapine 15 mg / Olanzapine 15 mg". The 'Asenapine 2.5 mg Overall' arm represents the 'Placebo / Asenapine 2.5 mg' and 'Asenapine 2.5 mg / Asenapine 2.5 mg' arms combined and this combined arm was not included for analysis of this secondary end point. |
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
PANSS Marder Factor Anxiety/Depression Symptom Score at Days 7, 28, 84, 182, and Study Endpoint [12] | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
This measure reports results for the 4 items of the Marder anxiety/depression factor of the PANSS, which is a 30-item clinician-rated instrument used to assess schizophrenia symptoms. Marder factors are a modified grouping of the 30 PANSS items. For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. PANSS Marder factor anxiety/depression symptom score for each participant was sum of rating assigned to each of the 4 applicable Marder factor items, and ranged from 4 to 28 with a higher score indicating greater severity of symptoms. Population for analysis was the FAS, defined as all randomized participants from PO5688 who received ≥1 dose of study drug in PO5689 and had ≥1 post- PANSS Total Score measurement.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Days 7, 28, 84, 182, and Study Endpoint
|
|||||||||||||||||||||||||||||||||||||||||||||
Notes [12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The end point "PANSS Marder Factor Anxiety/Depression Symptom Score" was assessed in each of the individual treatment arms: "Placebo / Asenapine 2.5 mg"; "Asenapine 2.5 mg / Asenapine 2.5 mg"; "Asenapine 5 mg / Asenapine 5 mg" and "Olanzapine 15 mg / Olanzapine 15 mg". The 'Asenapine 2.5 mg Overall' arm represents the 'Placebo / Asenapine 2.5 mg' and 'Asenapine 2.5 mg / Asenapine 2.5 mg' arms combined and this combined arm was not included for analysis of this secondary end point. |
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Up to 30 days after last dose of study drug (up to approximately 30 weeks)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Analysis population was the ATS which included all randomized subjects from the short-term trial (PO5688) who received ≥1 dose of study drug in the current extension trial (PO5689).
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
17.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo / Asenapine 2.5 mg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
In the previous short-term trial PO5688, participants were administered placebo for 42 days; in the current extension trial (PO5689), participants were administered one 2.5 mg asenapine tablet BID for 26 weeks. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Asenapine 2.5 mg / Asenapine 2.5 mg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
In the previous short-term trial PO5688, participants were administered one 2.5 mg asenapine tablet BID for 42 days; in the current extension trial (PO5689), participants were assigned to the same treatment regimen (ie, one 2.5 mg asenapine tablet BID) for 26 weeks. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Asenapine 2.5 mg Overall
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
In the previous short-term trial PO5688, participants were administered either placebo or one 2.5 mg asenapine tablet BID for 42 days; in the current extension trial (PO5689), participants were administered one 2.5 mg asenapine tablet BID for 26 weeks. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Asenapine 5 mg / Asenapine 5 mg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
In the previous short-term trial PO5688, participants were administered one 5 mg asenapine tablet BID for 42 days; in the current extension trial (PO5689), participants were assigned to the same treatment regimen (ie, one 5 mg asenapine tablet BID) for 26 weeks. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Olanzapine 15 mg / Olanzapine 15 mg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
In the previous short-term trial PO5688, participants were administered 15 mg olanzapine (as one 10 mg and one 5 mg tablet) QD for 42 days (except during Week 1 when olanzapine 10 mg QD was administered); in the current extension trial (PO5689), participants were assigned to the same treatment regimen (ie, 15 mg olanzapine) for 26 weeks. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
10 Jan 2012 |
• In the list of medications prohibited prior to baseline and during trial, 'antiemetics containing dopamine agonist' was changed to 'antiemetics containing dopamine antagonists'.
• The lists of urinalysis tests was updated to include urine pregnancy test, urine drug screen, nitrite, urobilinogen, and leukocyte esterase and deleted microscopic examination.
• The Serious Adverse Event (SAE) section was updated to include 'cancer' as SAE outcome #6.
• Text regarding drug induced liver injury was updated, including text on monitoring liver enzymes to align with Merck standards and latest guidance of the Food and Drug Administration.
• Two additional closely monitored events were added: “suicidal ideation and/or behavior” and “drug hypersensitivity reactions”.
• Text regarding medication errors in three sections of the protocol was deleted.
• “Incidents associated with the device” was deleted from the list of events requiring expedited reporting of safety observations by the investigator to the sponsor.
• In the Tier 3 list of safety endpoints, “heart rate” was replaced with “pulse rate”. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |